New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 8, 2014
04:55 EDTBCR, BCR, ISIS, ISIS, TRVN, TRVN, SGEN, SGEN, ONCS, ONCS, KBIO, KBIO, GNMK, GNMK, LXRX, LXRX, ACAD, ACAD, EXAM, EXAMNeedham to hold a conference
Life Sciences Conference is being held in New York on April 8-9.
News For BCR;ACAD;LXRX;GNMK;KBIO;ONCS;SGEN;TRVN;ISIS;EXAM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 26, 2014
14:28 EDTBCRMedtronic agrees to divest Covidien drug-coated balloon catheter business
Medtronic (MDT) has agreed to divest the drug-coated balloon catheter business of Covidien (COV) in order to settle Federal Trade Commission charges that its $42.9B acquisition of Covidien would likely be anticompetitive. Under the FTC’s proposed settlement, Medtronic will sell the drug-coated balloon catheter business to medical device company Spectranetics (SPNC), the FTC announced. According to the FTC’s complaint both Medtronic and Covidien are developing drug-coated balloon catheters to compete with C.R. Bard (BCR), which currently is the only company that supplies these products, used to treat peripheral artery disease, in the U.S. market. Medtronic and Covidien are the only companies with products in clinical trials in the Food and Drug Administration’s approval process, which makes it unlikely that other competitors could enter the market in time to counteract the effects of the merger, the FTC alleges. The Commission vote to accept the proposed consent order for public comment was 5-0. The FTC will publish the consent agreement package in the Federal Register shortly. The agreement will be subject to public comment for 30 days, beginning today and continuing through December 29, after which the Commission will decide whether to make the proposed consent order final.
November 25, 2014
07:09 EDTISISIsis Pharmaceuticals initiates pivotal Phase 3 study evaluating ISIS-SMN
Subscribe for More Information
November 21, 2014
09:17 EDTLXRX, ACADOn The Fly: Pre-market Movers
Subscribe for More Information
08:30 EDTACADACADIA initiated with an Outperform at Cowen
Target $46.
06:27 EDTLXRXLexicon 49.751M share Spot Secondary priced at $1.005
Subscribe for More Information
November 20, 2014
09:29 EDTACADACADIA management to meet with Piper Jaffray
Meetings to be held in Europe November 27 and 28 Piper Jaffray.
07:24 EDTISISGoldman to hold a conference
Subscribe for More Information
07:13 EDTGNMKCanaccord to hold a forum
Subscribe for More Information
06:40 EDTISISIsis Pharmaceuticals price target raised to $62 from $53 at Piper Jaffray
Subscribe for More Information
November 19, 2014
16:11 EDTLXRXLexicon files to sell $50M of common stock
Subscribe for More Information
November 18, 2014
15:48 EDTISISGenzyme, Isis present KYNAMRO data at AHA meeting
Genzyme, a Sanofi (SNY) company, and Isis Pharmaceuticals (ISIS) announced that new two-year data from a phase 3 long-term extension study of KYNAMRO injection was presented at a scientific session at the annual American Heart Association meeting. In the study, a retrospective analysis showed that patients treated with KYNAMRO for a mean of two years had a significant reduction in Major Adverse Cardiovascular Events compared to two years prior to therapy. The rate of MACE in patients treated with KYNAMRO for two years were adjudicated by an independent committee and compared to the rate of MACE in the same patients based on their medical history prior to treatment with KYNAMRO. In this analysis, MACE were identified in 62% of patients during two years prior to KYNAMRO treatment, and 9% of patients during a mean of 24.4 months after initiation of treatment with KYNAMRO.
07:32 EDTTRVNTrevena price target raised to $21 from $18 at JMP Securities
Subscribe for More Information
07:21 EDTACADUBS to hold a field trip
Subscribe for More Information
06:08 EDTONCSOncoSec announces preclinical collaboration with Plexxikon
Subscribe for More Information
November 17, 2014
19:01 EDTACADACADIA management to meet with Piper Jaffray
Subscribe for More Information
16:04 EDTTRVNTrevena reports TRV130 Phase 2a/b Study achieved primary endpoint
Subscribe for More Information
November 14, 2014
15:41 EDTISISIsis Pharmaceuticals management to meet with Piper Jaffray
Meeting to be held in Kansas City, MO on November 18 hosted by Piper Jaffray.
November 13, 2014
12:05 EDTONCSOncoSec management to meet with Maxim
Meeting to be held in Dallas on November 20 hosted by Maxim.
12:04 EDTONCSOncoSec management to meet with Maxim
Meeting to be held in Chicago on November 17 hosted by Maxim.
05:34 EDTISISAstraZeneca, Isis Pharmaceuticals to co-develop oligonucleotide delivery methods
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use